{"title":"制造业","authors":"E. Ruspini, P. Bonissone, W. Pedrycz","doi":"10.18356/c08601fa-en-fr","DOIUrl":null,"url":null,"abstract":": 1 SARS-CoV-2 may present risk to patients treated with donor-derived microbiome therapies 2 when lacking appropriate manufacturing controls and inactivation processes. We report that the 3 manufacturing steps for SER-109, a purified investigational microbiome therapeutic developed 4 to reduce risk of Clostridioides difficile recurrence, inactivate Porcine Epidemic Diarrhea Virus, 5 a model coronavirus for SARS-CoV-2. 6","PeriodicalId":165433,"journal":{"name":"Handbook of Fuzzy Computation","volume":"306 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2020-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Manufacturing\",\"authors\":\"E. Ruspini, P. Bonissone, W. Pedrycz\",\"doi\":\"10.18356/c08601fa-en-fr\",\"DOIUrl\":null,\"url\":null,\"abstract\":\": 1 SARS-CoV-2 may present risk to patients treated with donor-derived microbiome therapies 2 when lacking appropriate manufacturing controls and inactivation processes. We report that the 3 manufacturing steps for SER-109, a purified investigational microbiome therapeutic developed 4 to reduce risk of Clostridioides difficile recurrence, inactivate Porcine Epidemic Diarrhea Virus, 5 a model coronavirus for SARS-CoV-2. 6\",\"PeriodicalId\":165433,\"journal\":{\"name\":\"Handbook of Fuzzy Computation\",\"volume\":\"306 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-03-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Handbook of Fuzzy Computation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.18356/c08601fa-en-fr\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Handbook of Fuzzy Computation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18356/c08601fa-en-fr","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
: 1 SARS-CoV-2 may present risk to patients treated with donor-derived microbiome therapies 2 when lacking appropriate manufacturing controls and inactivation processes. We report that the 3 manufacturing steps for SER-109, a purified investigational microbiome therapeutic developed 4 to reduce risk of Clostridioides difficile recurrence, inactivate Porcine Epidemic Diarrhea Virus, 5 a model coronavirus for SARS-CoV-2. 6
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
